Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
VMF
0
API
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
Finished Drug Prices
NA
1. 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)ethanol
2. Atarax
3. Durrax
4. Hydroxyzine
5. Hydroxyzine Dihydrochloride
6. Hydroxyzine Hydrochloride
7. Orgatrax
8. Pamoate, Hydroxyzine
9. Vistaril
1. 10246-75-0
2. Hydroxyzine Embonate
3. Bobsule
4. Hydroxyzine (pamoate)
5. Equipose
6. Hydroxyzine Pamoate Salt
7. Hy-pam
8. Nsc-757063
9. Mls000028605
10. M20215mufr
11. Masmoran
12. Paxisitil
13. Smr000058728
14. Atarax P
15. 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic Acid;2-[2-[4-[(4-chlorophenyl)-phenylmethyl]piperazin-1-yl]ethoxy]ethanol
16. Sr-01000003149
17. Einecs 233-582-1
18. Unii-m20215mufr
19. Hydroxyzine Pamoate [usp:jan]
20. Atarax-p (tn)
21. Spectrum_000911
22. Vistaril Pamoate (tn)
23. Spectrum2_001000
24. Spectrum3_000463
25. Spectrum4_000013
26. Spectrum5_000838
27. Hyydroxyzine Pamoate
28. 6-ethylthiomorpholin-3-one
29. Schembl41333
30. Bspbio_002166
31. Kbiogr_000385
32. Kbioss_001391
33. 2-(2-(4-(p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)ethanol 4,4'-methylenebis(3-hydroxy-2-naphthoate) (1:1)
34. Divk1c_000503
35. Spectrum1500345
36. Spbio_001099
37. Chembl1200467
38. Hydroxyzine Pamoate [mi]
39. Hms501j05
40. Kbio1_000503
41. Kbio2_001391
42. Kbio2_003959
43. Kbio2_006527
44. Kbio3_001386
45. Dtxsid00907580
46. Hydroxyzine Pamoate [jan]
47. Hydroxyzine Pamoate (jp17/usp)
48. Ninds_000503
49. Hms1920f11
50. Hms2091l19
51. Hms2235o19
52. Hms3886g14
53. Pharmakon1600-01500345
54. Hydroxyzine Pamoate [vandf]
55. Hy-b0895
56. Ccg-40218
57. Hydroxyzine Embonate [mart.]
58. Hydroxyzine Pamoate [usp-rs]
59. Mfcd00058051
60. Nsc757063
61. S5649
62. Hydroxyzine Embonate [who-dd]
63. Akos015914218
64. Nsc 757063
65. Idi1_000503
66. Hydroxyzine Pamoate [orange Book]
67. Ncgc00021152-02
68. Ncgc00021152-03
69. Ncgc00094698-01
70. Ncgc00094698-02
71. (+-)-2-(2-(4-(p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)ethanol 4,4'-methylenebis(3-hydroxy-2-naphthoate) (1:1)
72. Ethanol, 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, (+-)-, Compd. With 4,4'-methylenebis(3-hydroxy-2-naphthalenecarboxylic Acid) (1:1)
73. Ethanol, 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, Compd. With 4,4'-methylenebis(3-hydroxy-2-naphthalenecarboxylic Acid) (1:1)
74. Hydroxyzine Pamoate [usp Monograph]
75. Sbi-0051413.p003
76. Ft-0697190
77. Hydroxyzine Pamoate Salt, Analytical Standard
78. D01096
79. F15112
80. J-000695
81. Sr-01000003149-2
82. Sr-01000003149-4
83. Q27114645
84. Hydroxyzine Pamoate, United States Pharmacopeia (usp) Reference Standard
85. (+/-)-2-(2-(4-(p-chloro-.alpha.-phenylbenzyl)-1-piperazinyl)ethoxy)ethanol 4,4'-methylenebis(3-hydroxy-2-naphthoate) (1:1)
86. Ethanol, 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, (+/-)-, Compd. With 4,4'-methylenebis(3-hydroxy-2-naphthalenecarboxylic Acid) (1:1)
Molecular Weight | 763.3 g/mol |
---|---|
Molecular Formula | C44H43ClN2O8 |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 12 |
Exact Mass | 762.2707940 g/mol |
Monoisotopic Mass | 762.2707940 g/mol |
Topological Polar Surface Area | 151 Ų |
Heavy Atom Count | 55 |
Formal Charge | 0 |
Complexity | 945 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Hydroxyzine pamoate |
PubMed Health | Hydroxyzine Pamoate (By mouth) |
Drug Classes | Antianxiety, Antiemetic, Respiratory Agent |
Drug Label | Hydroxyzine pamoate is designated chemically as 1-(p-chlorobenzhydryl) 4-[2-(2-hydroxyethoxy) ethyl] diethylenediamine salt of 1,1'-methylene bis (2 hydroxy-3-naphthalene carboxylic acid). It has the following structural formula: C21H27ClN2O2C23H1... |
Active Ingredient | Hydroxyzine pamoate |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 50mg hydrochloride; eq 50mg hcl; eq 100mg hcl; eq 25mg hcl; eq 25mg hydrochloride |
Market Status | Prescription |
Company | Sandoz; Watson Labs; Emcure Pharms Usa; Barr |
2 of 2 | |
---|---|
Drug Name | Hydroxyzine pamoate |
PubMed Health | Hydroxyzine Pamoate (By mouth) |
Drug Classes | Antianxiety, Antiemetic, Respiratory Agent |
Drug Label | Hydroxyzine pamoate is designated chemically as 1-(p-chlorobenzhydryl) 4-[2-(2-hydroxyethoxy) ethyl] diethylenediamine salt of 1,1'-methylene bis (2 hydroxy-3-naphthalene carboxylic acid). It has the following structural formula: C21H27ClN2O2C23H1... |
Active Ingredient | Hydroxyzine pamoate |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 50mg hydrochloride; eq 50mg hcl; eq 100mg hcl; eq 25mg hcl; eq 25mg hydrochloride |
Market Status | Prescription |
Company | Sandoz; Watson Labs; Emcure Pharms Usa; Barr |
Histamine H1 Antagonists
Drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. Included here are the classical antihistaminics that antagonize or prevent the action of histamine mainly in immediate hypersensitivity. They act in the bronchi, capillaries, and some other smooth muscles, and are used to prevent or allay motion sickness, seasonal rhinitis, and allergic dermatitis and to induce somnolence. The effects of blocking central nervous system H1 receptors are not as well understood. (See all compounds classified as Histamine H1 Antagonists.)
Antipruritics
Agents, usually topical, that relieve itching (pruritus). (See all compounds classified as Antipruritics.)
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-09-07
Pay. Date : 2023-07-27
DMF Number : 38535
Submission : 2023-07-03
Status : Active
Type : II
NDC Package Code : 66022-0122
Start Marketing Date : 2023-06-23
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-09-28
Pay. Date : 2013-09-24
DMF Number : 4514
Submission : 1982-04-16
Status : Active
Type : II
Registration Number : 218MF11037
Registrant's Address : Via Colleoni 15/17, 24040 Ciserano(BG)・Italy
Initial Date of Registration : 2006-12-28
Latest Date of Registration : --
NDC Package Code : 51604-0004
Start Marketing Date : 2009-10-14
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2024-09-04
Pay. Date : 2024-08-13
DMF Number : 36954
Submission : 2022-03-31
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3508
Submission : 1979-04-18
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4629
Submission : 1982-08-11
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2808
Submission : 1976-11-29
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3695
Submission : 1980-01-16
Status : Inactive
Type : II
NDC Package Code : 49711-1508
Start Marketing Date : 2009-10-23
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 13746-111
Start Marketing Date : 2012-10-31
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4629
Submission : 1982-08-11
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-09-28
Pay. Date : 2013-09-24
DMF Number : 4514
Submission : 1982-04-16
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3508
Submission : 1979-04-18
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2808
Submission : 1976-11-29
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2024-09-04
Pay. Date : 2024-08-13
DMF Number : 36954
Submission : 2022-03-31
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2023-09-07
Pay. Date : 2023-07-27
DMF Number : 38535
Submission : 2023-07-03
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 3695
Submission : 1980-01-16
Status : Inactive
Type : II
NDC Package Code : 51604-0004
Start Marketing Date : 2009-10-14
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (50kg/50kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 57451-1217
Start Marketing Date : 2022-03-28
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 51927-2316
Start Marketing Date : 2013-06-25
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT FOR HUMAN P...
NDC Package Code : 49452-3659
Start Marketing Date : 1996-09-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
NDC Package Code : 13746-111
Start Marketing Date : 2012-10-31
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 66022-0122
Start Marketing Date : 2023-06-23
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 49711-1508
Start Marketing Date : 2009-10-23
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Hydroxyzine Pamoate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Hydroxyzine Pamoate, including repackagers and relabelers. The FDA regulates Hydroxyzine Pamoate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Hydroxyzine Pamoate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Hydroxyzine Pamoate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Hydroxyzine Pamoate supplier is an individual or a company that provides Hydroxyzine Pamoate active pharmaceutical ingredient (API) or Hydroxyzine Pamoate finished formulations upon request. The Hydroxyzine Pamoate suppliers may include Hydroxyzine Pamoate API manufacturers, exporters, distributors and traders.
click here to find a list of Hydroxyzine Pamoate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Hydroxyzine Pamoate DMF (Drug Master File) is a document detailing the whole manufacturing process of Hydroxyzine Pamoate active pharmaceutical ingredient (API) in detail. Different forms of Hydroxyzine Pamoate DMFs exist exist since differing nations have different regulations, such as Hydroxyzine Pamoate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Hydroxyzine Pamoate DMF submitted to regulatory agencies in the US is known as a USDMF. Hydroxyzine Pamoate USDMF includes data on Hydroxyzine Pamoate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Hydroxyzine Pamoate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Hydroxyzine Pamoate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Hydroxyzine Pamoate Drug Master File in Japan (Hydroxyzine Pamoate JDMF) empowers Hydroxyzine Pamoate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Hydroxyzine Pamoate JDMF during the approval evaluation for pharmaceutical products. At the time of Hydroxyzine Pamoate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Hydroxyzine Pamoate suppliers with JDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Hydroxyzine Pamoate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Hydroxyzine Pamoate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Hydroxyzine Pamoate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Hydroxyzine Pamoate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Hydroxyzine Pamoate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Hydroxyzine Pamoate suppliers with NDC on PharmaCompass.
Hydroxyzine Pamoate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Hydroxyzine Pamoate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Hydroxyzine Pamoate GMP manufacturer or Hydroxyzine Pamoate GMP API supplier for your needs.
A Hydroxyzine Pamoate CoA (Certificate of Analysis) is a formal document that attests to Hydroxyzine Pamoate's compliance with Hydroxyzine Pamoate specifications and serves as a tool for batch-level quality control.
Hydroxyzine Pamoate CoA mostly includes findings from lab analyses of a specific batch. For each Hydroxyzine Pamoate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Hydroxyzine Pamoate may be tested according to a variety of international standards, such as European Pharmacopoeia (Hydroxyzine Pamoate EP), Hydroxyzine Pamoate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Hydroxyzine Pamoate USP).
LOOKING FOR A SUPPLIER?